It is worth noting, however, that DA/AA IDH-wildtype (DA/AA IDHwt) harboring genomic abnormalities typically associated with GBM, i.e. TERTp mutations, or EGFR amplification, or gain of whole chromosome 7 in combination with monosomy of chromosome 10, have a clinical outcome similar to, or only slightly longer, than GBM [4]. This evidence concerns the gene IDH2 and glioblastoma.